Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 22, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on May 6, 2024, which is part of a broader 12-month programme approved to repurchase up to DKK 20 billion in shares.
Key Financial Metrics and Transaction Details
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow). Key metrics provided include:
- Total Repurchase Programme Cap: Up to DKK 20 billion (12-month period starting February 6, 2024).
- Specific Sub-Programme (May 6 - Aug 5, 2024): Up to DKK 2.2 billion.
- Cumulative Repurchases (Feb 6 - July 19, 2024): 10,619,037 B shares.
- Cumulative Transaction Value (Feb 6 - July 19, 2024): DKK 9,326,780,889.
- Average Share Price (Feb 6 - July 19, 2024): DKK 878.31 per B share.
- Treasury Shares Held: 11,984,827 B shares (0.3% of share capital).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Activity
The filing details specific transactions executed between July 15 and July 19, 2024, under the sub-programme initiated in May:
| Date | Number of B Shares | Avg. Purchase Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| July 15, 2024 | 36,968 | 980.84 | 36,259,639 |
| July 16, 2024 | 37,000 | 972.00 | 35,963,993 |
| July 17, 2024 | 37,999 | 930.48 | 35,357,395 |
| July 18, 2024 | 37,500 | 916.73 | 34,377,441 |
| July 19, 2024 | 37,500 | 907.23 | 34,020,989 |
Accumulated transactions under the May 6, 2024 programme total 1,884,787 shares with a value of DKK 1,799,046,117.
Guidance, Outlook, and Management Commentary
Outlook: Novo Nordisk expects to continue repurchasing B shares for an amount up to DKK 20 billion during the 12-month period beginning February 6, 2024. As of July 19, 2024, the company has utilized approximately 46.6% of the total programme cap.
Management Commentary: The company reaffirms its purpose to drive change to defeat serious chronic diseases, built upon its heritage in diabetes. The repurchase programme is executed in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond standard regulatory compliance for share buybacks.
Important Facts for Investors to Verify
- Programme Progress: Verify the remaining capacity of the DKK 20 billion buyback programme (approx. DKK 10.67 billion remaining as of July 19).
- Treasury Share Impact: Confirm the impact of 11,984,827 treasury shares (0.3% of capital) on earnings per share (EPS) calculations in future reports.
- Share Price Volatility: Note the fluctuation in average purchase prices during the week of July 15-19, ranging from DKK 907.23 to DKK 980.84.
- Operational Data: This filing contains no operational financial data; investors must refer to the most recent Form 20-F or quarterly reports for revenue and profit metrics.